I. CALL TO ORDER
   a. The meeting was called to order shortly after 2 pm and introductions were made.
   b. Conflict of interest declarations were reviewed; no new conflicts were disclosed.
   c. Minutes from the November 17, 2011 meeting were reviewed and one change noted.

   **ACTION:** Minutes were approved with recommended change.

II. PROCESS
   a. The procedure document was reviewed and accepted as is, but noted that it is a living document.

III. OLD BUSINESS
   a. Ms. Ketchum presented DUE on Methadone and Long-Acting Opioids. Public comment was presented during the November 17th meeting by Kathy Kirk and Kathy Hahn from the Oregon Pain Management Commission. Written testimony was provided by Dr. Roger Chou.

   **ACTION:** Methadone – New Starts @ doses >20mg: approved with recommendation of adding UDS and strengthening language for co-administration with benzodiazepines.

   **ACTION:** Opioids – Long-Acting: approved with recommendation of adding UDS.

   **ACTION:** Opioids – Long-Acting – High Dose Limit: approved with recommendation of adding UDS.

IV. NEW BUSINESS
   a. Mr. Citron presented a dose consolidation concept for committee member comments.

   **ACTION:** The committee recommended bringing a list of drugs or classes the Authority would like reviewed. The committee also recommended a dose consolidation review is done with each class review in the future.

   b. Mr. Magrish presented the New Drug Policy as specified in 410-121-0040(5)(a-c).

   **ACTION:** Approved.

*Agenda items with an asterisk will be discussed by Committee members for the purpose of making recommendations to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9)*
c. Dr. Sentena presented DUE for adding Oral Anticoagulants class to the Preferred Drug List (PDL) and making Warfarin a preferred product.

*ACTION: Approved.

1. Dr. Sentena presented DUE and recommended keeping Pradaxa (dabigatran) as non-preferred requiring prior authorization (Oral Direct Thrombin Inhibitors).

*ACTION: Approved after Executive Session with recommendation to add GFR limits to #1 and add “unstable INR” to #6.

2. Dr. Sentena presented DUE and recommended keeping Xarelto (rivaroxaban) as non-preferred requiring prior authorization (Oral Direct Factor Xa Inhibitors). Laura Litzenberger from Janssen Scientific Affairs presented public comment for Xaralot.

*ACTION: Approved after Executive Session with recommendation of making 3rd line after Pradaxa.

d. Dr. Herink presented DUE and recommended expanding the current Hepatitis C drug class to include all agents for treatment of chronic Hepatitis C virus and maintain either one or both of peginterferon alfa-2a (Pegasys) and peginterferon alfa-2b (Pegintron) as preferred products and require prior authorization (Pegylated Interferon and Ribavirin). Lorren Sandt from Caring Ambassadors presented public comment on Hepatitis C.

ACTION: Committee asked to see cost evaluations per package size and bring back to February meeting.

1. Dr. Willard presented DUE and recommended prior authorization criteria (Hepatitis C Oral Protease Inhibitors/Triple Therapy) on Incivek (telaprevir). Dr. Jamie Tobitt form Vertex presented public comment on telaprevir.

2. Dr. Willard presented DUE and recommended prior authorization criteria (Hepatitis C Oral Protease Inhibitors/Triple Therapy)Victrelis (boceprevir). Vic Benson from Merck presented public comment on boceprevir.

*ACTION: Hepatitis C Oral Protease Inhibitors/Triple Therapy: approved after Executive Session with recommendation of including the more generous of the choice (e.g. male or female, platelet count, etc.). Recommended monitoring these clients through the Disease Case Management or Medication Therapy Management programs.

e. Dr. Herink presented DUE on the ACE-Is/ARBs/DRI class and recommended maintaining all DRI’s and products containing a DRI as non-preferred; keeping Edarbi (azilsartan) as non-preferred ARB; and making PDL recommendations based on cost since no new significant clinical evidence exists since the class was last reviewed.

*ACTION: Approved after Executive Session.

f. Dr. Herink presented drug class scans.

1. HSV Antivirals
2. Influenza Antivirals
3. Beta Blockers
4. Calcium Channel Blocker

ACTION: Approved after Executive Session.

VII. FUTURE BUSINESS

The next meeting will be on February 23, 2012 in Wilsonville. The March meeting will be held on the 29th instead of the originally scheduled 26th in Salem.

VIII. ADJOURN

The meeting adjourned at 4:25pm.

Agenda items with an asterisk will be discussed by Committee members for the purpose of making recommendations to the Oregon Health Plan for adoption into Oregon Administrative Rules 410-121-0030 & 410-121-0040 as required by 414.325(9)